Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial

BACKGROUND: Continuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis. Although this therapy is well known in Japan, its efficacy and safety remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirota, Morihisa, Shimosegawa, Tooru, Kitamura, Katsuya, Takeda, Kazunori, Takeyama, Yoshifumi, Mayumi, Toshihiko, Ito, Tetsuhide, Takenaka, Mamoru, Iwasaki, Eisuke, Sawano, Hirotaka, Ishida, Etsuji, Miura, Shin, Masamune, Atsushi, Nakai, Yousuke, Mitoro, Akira, Maguchi, Hiroyuki, Kimura, Kenji, Sanuki, Tsuyoshi, Ito, Tetsuya, Haradome, Hiroki, Kozaka, Kazuto, Gabata, Toshifumi, Kataoka, Keisho, Hirota, Masahiko, Isaji, Shuji, Nakamura, Ryoji, Yamagiwa, Koki, Kayaba, Chie, Ikeda, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026212/
https://www.ncbi.nlm.nih.gov/pubmed/31758329
http://dx.doi.org/10.1007/s00535-019-01644-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026212/
https://www.ncbi.nlm.nih.gov/pubmed/31758329
http://dx.doi.org/10.1007/s00535-019-01644-z

Ejemplares similares